SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
Gastrointestinal Cancer, Hematologic Cancer, Thoracic Cancer
SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
-
Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, Massachusetts, United States, 02135
Dana-Farber Cancer Instiute - Merrimack Valley, Methuen, Massachusetts, United States, 01844
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Nadine McCleary, MD, MPH,
Nadine J McCleary, MD MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute
2025-07-30